AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.
Phase 2 will also include various subjects who received the highest dose, AIM said.
The company said that up to 25 patients are expected to be enrolled in the study's phase 2.
AIM shares were down over 8% in recent trading.
Price: 0.12, Change: -0.01, Percent Change: -8.44
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。